XtalPi Holdings（QNTP.F）株式概要投資持株会社のXtalPi Holdings Limitedは、中国本土、米国、および国際的なロボット工学と創薬ソリューションの提供に従事している。 詳細QNTP.F ファンダメンタル分析スノーフレーク・スコア評価0/6将来の成長5/6過去の実績2/6財務の健全性3/6配当金0/6報酬収益は年間62.44%増加すると予測されています 今年は黒字化を達成 リスク分析高いレベルの非現金収入 US市場と比較して、過去 3 か月間の株価の変動が非常に大きいすべてのリスクチェックを見るQNTP.F Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair ValueUS$Current PriceUS$1.1029.5% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-2b3b2016201920222025202620282031Revenue CN¥2.6bEarnings CN¥399.0mAdvancedSet Fair ValueView all narrativesXtalPi Holdings Limited 競合他社Sotera HealthSymbol: NasdaqGS:SHCMarket cap: US$4.5bStevanato GroupSymbol: NYSE:STVNMarket cap: US$4.9bBrukerSymbol: NasdaqGS:BRKRMarket cap: US$7.0b10x GenomicsSymbol: NasdaqGS:TXGMarket cap: US$3.0b価格と性能株価の高値、安値、推移の概要XtalPi Holdings過去の株価現在の株価HK$1.1052週高値HK$2.0452週安値HK$0.60ベータ01ヶ月の変化0%3ヶ月変化-33.33%1年変化n/a3年間の変化n/a5年間の変化n/aIPOからの変化10.00%最新ニュースお知らせ • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.お知らせ • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen Chinaお知らせ • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026お知らせ • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.お知らせ • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listingお知らせ • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing最新情報をもっと見るRecent updatesお知らせ • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.お知らせ • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen Chinaお知らせ • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026お知らせ • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.お知らせ • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listingお知らせ • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listingお知らせ • Aug 15XtalPi Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025XtalPi Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025お知らせ • Jun 13XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited.XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited on June 12, 2025. XtalPi Holdings Limited (SEHK:2228) completed the acquisition of Liverpool ChiroChem Limited on June 12, 2025.株主還元QNTP.FUS Life SciencesUS 市場7D0%4.1%1.1%1Yn/a8.3%28.7%株主還元を見る業界別リターン: QNTP.FがUS Life Sciences業界に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。リターン対市場: QNTP.F US市場に対してどのようなパフォーマンスを示したかを判断するにはデータが不十分です。価格変動Is QNTP.F's price volatile compared to industry and market?QNTP.F volatilityQNTP.F Average Weekly Movement25.3%Life Sciences Industry Average Movement8.0%Market Average Movement7.2%10% most volatile stocks in US Market16.5%10% least volatile stocks in US Market3.1%安定した株価: QNTP.Fの株価は、 US市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 過去 1 年間のQNTP.Fのボラティリティの変化を判断するには データが不十分です。会社概要設立従業員CEO（最高経営責任者ウェブサイト20151,203Jian Mawww.xtalpi.com投資持株会社のXtalPi Holdings Limitedは、中国本土、米国、および国際的なロボット工学と創薬ソリューションの提供に従事している。同社は、AI低分子創薬スマート計算プラットフォーム「XMolGen」、抗体-抗原複合体構造を予測し、主要相互作用部位を特定する抗体-抗原複合体構造予測プラットフォーム「XtalFold」、物理モデルとAIアルゴリズムの組み合わせにより蓄積された数十万件の結晶化データに基づいて化合物分子の物理化学的特性、結晶構造、安定性関係を予測する新世代の医薬品結晶化研究開発プラットフォーム「Xtalgazer」を提供している。また、自動化学合成サービス、Al+robotics実験室インテリジェント自動化ソリューションも提供している。さらに、AIを活用した特許データ抽出ツールであるPatSightは、最大12件の特許から主要データを自動抽出し、CSVファイルまたはSDFファイルとして編集可能な形式でSMILESを提供するほか、候補化合物と生物学的標的との親和性予測に使用するツールであるXFEPも提供している。さらに、ヒット化合物の発見、ヒット化合物やリード化合物の最適化、生物学的機能サービスからなる創薬ソリューション、自動化支援化学合成やフォーカス・ライブラリー・サービスを含む探索化学ソリューション、実験的固体研究開発、固体化学計算ソリューション、結晶構造決定を提供している。前身はQuantumPharm Inc.で、2024年12月にXtalPi Holdings Limitedに社名変更。XtalPi Holdings Limitedは2015年に設立され、中国の深センに本社を置いている。もっと見るXtalPi Holdings Limited 基礎のまとめXtalPi Holdings の収益と売上を時価総額と比較するとどうか。QNTP.F 基礎統計学時価総額US$4.37b収益（TTM）US$18.21m売上高(TTM)US$118.13m239.7xPER（株価収益率37.0xP/SレシオQNTP.F は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計QNTP.F 損益計算書（TTM）収益CN¥802.62m売上原価CN¥243.45m売上総利益CN¥559.18mその他の費用CN¥435.43m収益CN¥123.75m直近の収益報告Dec 31, 2025次回決算日該当なし一株当たり利益（EPS）0.029グロス・マージン69.67%純利益率15.42%有利子負債／自己資本比率3.7%QNTP.F の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/24 19:19終値2026/05/15 00:00収益2025/12/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋XtalPi Holdings Limited 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。5 アナリスト機関Yu WuCMB International Securities LimitedWing-Tai NgDeutsche BankYue-Kwong LuiJefferies LLC2 その他のアナリストを表示
お知らせ • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.
お知らせ • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen China
お知らせ • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026
お知らせ • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.
お知らせ • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
お知らせ • May 05Xtalpi and Pharmaengine Achieve Enrollment Milestone for Pep08 and Initiate Second Synthetic Lethality ProgramXtalPi (2228.HK), an AI- and robotics-powered innovation platform, announced dual breakthroughs in its strategic partnership with PharmaEngine (4162.TWO). PEP08, a next-generation PRMT5 inhibitor discovered via XtalPi's platform, has successfully begun enrollments in a Phase I solid tumor trial, achieving a new clinical milestone. Built upon the success of PEP08 at the drug discovery stage, the two companies initiated a second project, targeting a different undisclosed synthetic lethality mechanism. PEP08 received clinical clearance in June 2025 and is currently in Phase I evaluation for solid tumors in Australia and the Taiwan region. The enrollment milestone underscores XtalPi's ability to deliver differentiated molecules with strong drug-like properties, while demonstrating the program's steady clinical advancement. Leveraging XtalPi's integrated quantum physics-, AI-, and robotics-powered platform, PEP08 was designed to overcome the dose-limiting hematological toxicities seen with first-generation PRMT5 inhibitors. The molecule exploits an innovative MTA-cooperative binding mode to specifically target MTAP-deleted tumors—a genomic alteration found in 10-15% of all human cancers, with higher frequencies observed in NSCLC, pancreatic cancer, glioblastoma, and more. Preclinical data presented at 2025 AACR show PEP08 achieving superior efficacy compared to other clinical-stage MTA-cooperative PRMT5 inhibitors across multiple MTAP-deleted tumor models, supporting a potential best-in-class profile. Driven by the success of PEP08 at the drug discovery stage, the partnership expanded into a second project. By combining PharmaEngine's deep oncology expertise with XtalPi's AI and robotics molecular design engine, the duo aims to capture additional market share in the synthetic lethality space. Synthetic lethality is widely recognized as challenging yet highly promising frontier in oncology. According to Globocan and industry data, the global market is expected to grow from $4,200 million to $17,600 million by 2033, at a 17.3% CAGR. In recent years, several early-stage licensing deals in this space have exceeded $1,000 million, further underscoring the immense clinical value and commercial appetite for this category. The clinical advancement of PEP08 and the ongoing collaboration of the second project serve as a dual validation of XtalPi's AI+robotics discovery engine. By repeatedly meeting rigorous benchmarks in complex target spaces, XtalPi has built a reproducible innovation model that turns deep know-how into high-value clinical assets. Underpinned by a milestone-sharing structure, this model tightly aligns the platform's evolution with clinical success, quickly translating biological insights into tangible impact for partners and patients around the world.
お知らせ • Apr 19XtalPi Holdings Limited, Annual General Meeting, May 20, 2026XtalPi Holdings Limited, Annual General Meeting, May 20, 2026, at 15:00 China Standard Time. Location: multi-functional meeting room, 3/f, second phase, of the international biomedical industrial park, no. 2 hongliu road, futian district, shenzhen China
お知らせ • Mar 13XtalPi Holdings Limited to Report Fiscal Year 2025 Results on Mar 25, 2026XtalPi Holdings Limited announced that they will report fiscal year 2025 results at 4:00 PM, China Standard Time on Mar 25, 2026
お知らせ • Sep 09Xtalpi Inc. Announces Pep08 Receives Regulatory Clearances to Initiate Phase 1 Clinical Trials in Solid TumorXtalPi Inc. has announced that PEP08, a next-generation PRMT5 inhibitor candidate developed through its AI drug discovery collaboration with PharmaEngine, Inc. has received regulatory clearances to initiate Phase 1 clinical trials in solid tumors. Approvals include Australia'sHuman Research Ethics Committee (HREC), recognized by the Australian Therapeutic Goods Administration (TGA), and the food and drug authority of the Taiwan region (TFDA). This milestone triggered a payment to XtalPi under the partnership agreement. PRMT5 (Protein Arginine Methyltransferase 5) is a validated synthetic lethality target in tumors harboring homozygous MTAP deletion, which is related to poor prognosis and present in 10-15% of human cancers, including small cell lung cancer (NSCLC), mesothelioma, pancreatic cancer, glioblastoma multiforme (GBM), head and neck cancer, esophageal cancer, and bladder cancer. While PRMT5 inhibition offers a potent mechanism for targeted therapy, first-generation inhibitors face significant challenges in selectivity, resulting in dose-limiting toxicities and unmet medical needs. Leveraging its integrated drug discovery platform that combines quantum physics, AI, and large-scale robotic experiments, XtalPi partnered with PharmaEngine's scientific team to conduct de novo drug design. The AI platform generated a multi-million compound library for PRMT5, identifying novel lead series with exceptional potential and selectivity. Following iterative optimization through quantum physics and AI-powered ADMET screening, PEP08 emerged as the preclinical candidate (PCC) and advanced through IND-enabling studies by PharmaEngine. As a second-generation PRMT5 inhibitor with a novel scaffold, PEP08 demonstrates superior activity and selectivity. Its MTA-cooperative binding mode stabilizes a ternary complex with PRMT5, enabling highly selective target inhibition. This mechanism drives potent synthetic lethality efficacy against MTAP-deleted tumor cells while minimizing off-target effects on normal cells, highlighting significant therapeutic potential. Preclinical studies revealed PEP08's markedly improved safety profile compared to first-generation PRMT5 inhibitors, alongside favorable blood-brain barrier penetration and overall developability characteristics. The compound achieved robust in vivo efficacy across multiple animal models. Compared to other clinical-stage second-generation candidates, PEP08 exhibits potential best-in-class properties and compelling combination therapy opportunities. PharmaEngine presented these findings at the 2025 American Association for Cancer Research (AACR) Annual Meeting. PEP08's successful regulatory clearance and milestone achievement underscore XtalPi's platform-driven innovation capabilities and mark a pivotal advancement in its partnership with PharmaEngine. XtalPi remains committed to empowering partners to discover novel drug candidates addressing complex targets, accelerate the development of competitive pipeline projects, and deliver transformative medicines to patients worldwide.
お知らせ • Sep 04XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has completed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 30XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion.XtalPi Holdings Limited has filed a Follow-on Equity Offering in the amount of HKD 2.653338 billion. Security Name: Ordinary Shares Security Type: Common Stock Securities Offered: 285,920,000 Price\Range: HKD 9.28 Transaction Features: Subsequent Direct Listing
お知らせ • Aug 15XtalPi Holdings Limited to Report First Half, 2025 Results on Aug 27, 2025XtalPi Holdings Limited announced that they will report first half, 2025 results on Aug 27, 2025
お知らせ • Jun 13XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited.XtalPi Holdings Limited (SEHK:2228) acquired Liverpool ChiroChem Limited on June 12, 2025. XtalPi Holdings Limited (SEHK:2228) completed the acquisition of Liverpool ChiroChem Limited on June 12, 2025.
